
Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

Sam Clark, MD, PhD, the founder and CEO of Terran Biosciences shared all you need to know about the development of their schizophrenia treatment, TerXT.

In honor of Asian American/Pacific Islander Heritage Month, we had a discussion on how best to support AAPI youth and their families.

Petros Levounis, MD, MA, talks addiction, buprenorphine, his year as president of the APA, and more at the 2024 Annual Meeting.

What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?

What are the most effective approaches to SUD treatment in this unique patient population?

Rosine Perelberg, PhD, discusses psychoanalytic thought, social anthropology, and the future of psychoanalysis.

Rejoyn was recently cleared by the FDA, making it the first prescription digital therapeutic for major depressive disorder.

Join us in congratulating Dr Tampi on his recent win of the American Association for Geriatric Psychiatry’s Diversity Award!

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Learn more about the inaugural Black Youth Mental Health Clinical Case Conference Series at Yale Child Study Center, a 6-session event in 2024, that focuses on improving mental health care for Black youth and their families.

Frank Clark, MD, the Psychiatric Times Diversity & Inclusion Section Editor, was recently appointed president of The Greenville County Medical Society, the first Black doctor to serve in this role.

“Freudian thought has massively influenced not only modern understandings of mind and therapeutic treatment, but also modernism and many distinct visions of politics.”

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

Just because a patient has anxiety or past trauma does not mean they cannot enjoy this spooky holiday…

The senior vice president of research at the American Foundation for Suicide Prevention offers thoughts on suicide and students.

A recent survey found mental health and finances were some of the top stressors for college students.

The 988 Implementation Act was introduced on July 25. What impact will it have on care?

One professional psychiatrist shares his account of living with bipolar affective disorder.

A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.

Learn more about a comprehensive system of care for those who are in crisis and need immediate access to care, aided by the new 988 Suicide & Crisis Lifeline.